# A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

> **NCT01637402** · PHASE2 · COMPLETED · sponsor: **Terence Friedlander, MD** · enrollment: 41 (actual)

## Conditions studied

- Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01637402
- **Lead sponsor:** Terence Friedlander, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-13
- **Primary completion:** 2017-02-27
- **Final completion:** 2017-02-27
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01637402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01637402, "A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01637402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*